Molecular therapy for glioblastoma

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 5, 1999, Pages 545-552

  Karpati, George ^a   Li, Hewei ^a   Nalbantoglu, Josephine ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Glioblastoma; Neovascularization; Prodrug systems; Viral vectors

Indexed keywords

MATRIX METALLOPROTEINASE; ONCOLYTIC VIRUS; PRODRUG; VIRUS VECTOR;

ADENOVIRUS; CLINICAL FEATURE; CLONING VECTOR; ENZYME INHIBITION; GENE THERAPY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOMODULATION; INTRATUMORAL DRUG ADMINISTRATION; MOLECULAR BIOLOGY; NONHUMAN; PROGNOSIS; RETROVIRUS; REVIEW; SAFETY; TUMOR VASCULARIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRAIN NEOPLASMS; CELL CYCLE; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; GLIOBLASTOMA; GROWTH INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; MICE; NEOVASCULARIZATION, PATHOLOGIC; PRODRUGS; VIRUSES;

EID: 0032716530     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. CA Cancer J Clin (1994) 44:7-26.
2. Ampil FL, Nanda A, Willis BK, Apple S: Treatment In patients with glioblastoma multiforme and poor performance status: is it worthwhile? Radiat Med (1998) 16:109-112.
3. Scott JN, Rewcastle NB, Brasher PMA, Fulton D, Hagen NA, MacKinnon JA, Sutherland G, Caimcross JG, Forsyth P: Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci (1998) 25:197-201.
4. Coons SW: Anatomy and growth patterns of diffuse gliomas. In: The Gliomas. Berger MS, Wilson CB (Eds), WB Saunders Company, Philadelphia (1999):210-225.
5. Barker FG, Israel MA: Molecular genetics. In: The Gliomas. Berger MS, Wilson CB (Eds), WB Saunders Company, Philadelphia (1999):39-51.
6. von Deimling AHR, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia (1995) 15:328-338.
7. Van de Keift E: Molecular pathogenesis of astrocytoma and glioblastoma multiforme. Acta Neurochir (1997) 139:589-599.
8. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas In vivo. Nature (1992) 359:845-848.
9. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 359:843-845.
10. Moolten PL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res (1986) 46:5276-5281.
11. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 256:1550-1552.
12. Ram Z, Culver KW, Wallbridge S, Blaese RM, Oldfield EH: In situ retroviral-mediated gene transfer for the treatment of brain tumors In rats. Cancer Res (1993) 53:83-88.
13. Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL: Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild-type retrovirus kills other tumor cells. J Neurosci Res (1992) 33:493-503.
14. Flck J, Barker FG, Dazin P, Westphale EM, Beyer EC, Israel MA: The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA (1995) 92:11071-11075.
15. Huber BE, Austin EA, Richards CA, Davis ST, Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA (1994) 91:8302-8306.
16. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, Fine HA: Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nature Med (1996) 2:567-573.
17. Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, Hilton J, Chiocca EA, Breakefield XO: New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Geno Ther (1998) 9:1261-1273.
18. Cortés ML, de Felipe P, Martín V, Hughes MA, Izquierdo M: Successful use of a plant gene in the treatment of cancer in vivo. Gene Ther (1998) 5:1499-1507.
19. Ono Y, Ikeda K, Wei MX, Harsh GR, Tamiya T, Chiocca EA: Regression of experimental brain tumors with 6-thioxanthine and Escherichia coli gpt gene therapy. Hum Gene Ther (1997) 8:2043-2055.
20. Harris CC: Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst (1996) 88:1442-1455.
21. Miyashita T, Krajewski S, Krajewska M, Wang HG, Un HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2and bax gene expression in vitro and In vivo. Oncogens (1994) 9:1799-1805.
22. Miyashita T, Reed JC: Tumor suppressor p53 Is a direct transcriptional activator of the human bax gene. Cell (1995) 80:293-299.
23. Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH: p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 188:2033-2045.
24. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, el-Deiry WS: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet (1997) 17:141-143.
25. Geng L, Walter S, Melian E, Vaughan ATM: Transfection of a vector expressing wild-type p53 into cells of two human glioma cell lines enchances radiation toxicity. Radiat Res (1998) 150:31-37.
26. Badie B, Kramar MH, Lau R, Boothman DA, Economou JS, Black KL: Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J Neuro-oncol (1998) 37:217-222.
27. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ: Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA (1990) 87:6166-6170.
28. Asai A, Miyagi Y, Sugiyama A, Gamanuma M, Hong SH, Takamoto S, Nomura K, Matsutani M, Takakura K, Kuchino Y: Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol (1994) 19:259-268.
29. Van Meir EG, Roemer K, Diserens A-C, Kikuchi T, Rempel SA, Haas M, Huang H-JS, Friedmann T, de Tribolet N, Cavenee WK: Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc Natl Acad Sci USA (1995) 92:1008-1012.
30. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK: Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res (1996) 56:694-699.
31. Köck H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, Wills KN, Gregory RJ, Shepard HM, Westphal M, Maneval DC: Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer (1996) 67:808-815.
32. Li H, Lochmüller H, Yong VW, Karpati G, Nalbantoglu J: Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. J Neuropathol Exp Neurol (1997) 56:872-878.
33. Fueyo J, Gomez-Manzano C, Yung WKA, Liu T-J, Alemany R, Bruner JM, Chintala SK, Rao JS, Levin VA, Kyritsis AP: Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology (1998) 50:1307-1315.
34. Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Bookstein R: Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res (1998) 58:2331-2334.
35. Shinoura N, Yoshida Y, Sadata A, Hanada K-I, Yamamoto S, Kirino T, Asai A, Hamada H: Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. Hum Gene Ther (1998) 9:1983-1993.
36. O'Rourke DM, Qian X, Zhang HT, Davis JG, Nute E, Meinkoth J, Greene MI: Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains. Proc Natl Acad Sci USA (1997) 94:3250-3255.
37. Yamazaki H, Kijima H, Ohnishi Y, Abe Y, Oshika Y, Tsuchida T, Tokunaga T, Tsugu A, Ueyama Y, Tamaoki N, Nakamura M: Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst (1998) 90:581-587.
38. Kaetzel DM, Reid JD, Pedigo N, Zimmer SG, Boghaert ER: A dominant-negative mutant of the platelet-derived growth factor A-chain increases survival of hamsters implanted intracerebrally with the highly invasive C×T24-neo3 glioblastoma cell. J Neuro-oncol (1998) 39:33-46.
39. Resnicoff M, Li W, Basak S, Herlyn D, Baserga R, Rubin R: Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol Immunother (1996) 42:64-68.
40. Brem S, Cotran R, Folkman J: Tumor angiogenesis: A quantitative method for histologic grading. J Natl Cancer Inst (1972) 48:347-356.
41. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA (1994) 91:4082-4085.
42. Taki T, Ohnishi T, Arita N, Hiraga S, Saitoh Y, Izumoto S, Mori K, Hayakawa T: Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: Potent inhibition of tumor angiogenesis. J Neuro-oncol (1994) 19:251-258.
43. Plate KH, Breier G, Millbauer B, Ullrich A, Risau W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res (1993) 53:5822-5827.
44. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK: Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res (1999) 59:895-900.
45. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM, Cavenee WK: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA (1996) 93:8502-8507.
46. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H: Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res (1995) 55:5296-5301.
47. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (1994) 367:576-579.
48. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K: Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest (1997) 100:2072-2078.
49. Tanaka T, Cao Y, Folkman J, Fine HA: Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res (1998) 58:3362-3369.
50. Pamey IF, Petruk KG, Zhang C, Farr-Jones M, Sykes DB, Chang LJ: Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum Gene Ther (1997) 8:1073-1085.
51. Wallenfriedman MA, Conrad JA, DelaBarre L, Graupman PC, Lee G, Garwood M, Gregerson DS, Jean WC, Hall WA, Low WC: Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J Neurosurg (1999) 90:1064-1071.
52. Donson AM, Foreman NK: Adenovirus-mediated gene therapy in a glioblastoma vaccine model; specific antitumor immunity and abrogation of immunosuppression. J Neuro-oncol (1998) 40(3):205-214.
53. Li Z, Rakkar A, Katayose Y, Kim M, Shanmugam N, Srivastava S, Moul JW, McLeod DG, Cowan KH, Seth P: Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. Gene Ther (1998) 5:605-613.
54. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY: Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer (1996) 32A:636-640.
55. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med (1997) 3:1362-1368.
56. Husain SR, Behari N, Kreitman RJ, Pastan I, Puri RK: Complete regression of established human glioblastoma tumor xenograft by Interleukin-4 toxin therapy. Cancer Res (1998) 58:3649-3653.
57. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant Science (1991) 252:854-856.
58. Ikeda I, Ishikawa T, Wakimoto H, Silver JS, Deisbock TS, Finkelstein D, Harsh GR, Louis DN, Bartus RT, Hochberg FH, Chiocca EA: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Med (1999) 5:881-887.
59. Csatary LK, Bakacs T: Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. J Am Med Assoc (1999) 281:1588-1589.
60. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kim DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and anti-tumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med (1997) 3:639-645.
61. Price A, Shi Q, Morris D, Wilcox ME, Brasher PMA, Rewcastle NB, Shalinsky D, Zou H, Appelt K, Johnston RN, Yong VW, Edwards D, Forsyth P: Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res (1999) 5:845-854.
62. Galipeau J, Li H, Paquin A, Sicilia F, Karpati G, Nalbantoglu J: Vesicular stomatitis virus G pseudotyped retrovector mediates effective In vivo suicide gene delivery in experimental brain cancer. Cancer Res (1999) 59:2384-2394.
63. McKie EA, Graham DI, Brown SM: Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector - potential glioblastoma targeting. Gene Ther (1998) 5:440-450.
64. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG Jr, Fine HA: Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nature Med (1997) 3:1145-1149.
65. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT: Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res (1998) 58:5738-5748.
66. Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, Bartus RT: Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol (1996) 141:214-224.
67. Barth RF: Rat brain tumor models in experimental neurooncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neuro-oncol (1998) 36:91-102.
68. Weissenberger J, Steinbach JP, Malin G, Spada S, Rülicke T, Aguzzi A: Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene (1997) 14:2005-2013.
69. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med (1995) 1:938-943.
70. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA: Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med (1997) 3:437-442.
71. Li H, Alonso-Vanegas M, Colicos MA, Jung SS, Lochmüller H, Sadikot AF, Snipes GJ, Seth P, Karpati G, Nalbantoglu J: Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res (1999) 5:637-642.
72. Chen S-H, Shine HD, Goodman JC, Grossman RG, Woo SLC: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA (1994) 91:3054-3057.
73. Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, Hirschowrtz EA, Crystal R, Weichselbaum R, Kufe DW, Fine HA: In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther (1996) 7:713-720.
74. Beutler AS, Banck MS, Aguzzi A: Curing rat glioblastoma: immunotherapy or graft rejection? Science (1997) 276:20-21.
75. Beutler AS, Banck MS, Wedekind D, Hedrich HJ: Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. Hum Gene Ther (1999) 10:95-101.
76. Izquierdo M, Cortés ML, Martin V, de Felipe P, Izquierdo JM, Pérez-Higueras A, Paz JF, Isla A, Blázquez MG: Gene therapy in brain tumours: Implications of the size of glioblastoma on its curability. Acta Neurochir (1997) 68:111-117.
77. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med (1997) 3:1354-1361.
78. Stockhammer G, Brotchi J, Leblanc R, Bernstein M, Schackert G, Weber F, Ostertag C, Mulder NH, Mellstedt H, Seiler R, Yonekawa Y, Twerdy K, Kostron H, De Witte O, Lambermont M, Velu T, Laneuville P, Villemure JG, Rutka JT, Warnke P, Laseur M, Mooij JJ, Boethius J, Mariani L, Meyer M, Brändli C, Frei K, Konu D Gianella-Borradori A: Gene therapy for glioblastoma multiform: in vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. J Mol Med (1997) 75:300-304.
79. Klatzmann D, Valéry CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL, Philippen J: A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study group on gene therapy for glioblastoma. Hum Gene Ther (1998) 9:2595-2604.
80. Izquierdo M, Martín V, de Felipe P, Izquierdo JM, Pérez-Higueras A, Cortés ML, Paz JF, Isla A, Blázquez MG: Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy., Gene Ther (1996) 3:491-495.
81. Eck SL, Alavi JB, Alavi A, Davis A, Hackney D, Judy K, Mollman J, Phillips PC, Wheeldon EB, Wilson JM: Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial. Hum Gene Ther (1996) 7:1465-1482.
82. Shapiro WR: Bias In uncontrolled brain tumor trials. Can J Neurol Sci (1997) 24:269-270.